Insulin glargine (Lantus®);Le médicament du mois: Insuline glargine (Lantus®)

Revue Medicale de Liege

Volumn 59, Issue 2, 2004, Pages 110-114

  Scheen, A J ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b CHU SART TILMAN   (Belgium)

Author keywords

Diabetes mellitus; Hypoglycaemia; Insulin analogue; Insulin therapy; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN;

ANTIGENICITY; ARTICLE; BETA CHAIN; CARBOXY TERMINAL SEQUENCE; DRUG BLOOD LEVEL; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMMUNOGENICITY; INSULIN TREATMENT; MITOGENICITY; NIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; RECOMBINANT DNA TECHNOLOGY; REPRODUCIBILITY; RISK BENEFIT ANALYSIS;

DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 1842608426     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Diabetes Control and Complications Trial Research Group. - The effect of intensive treatment of diabetes on development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 1993, 329, 977-986.
2. UK Prospective Diabetes Study Group. - Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet, 1998, 352, 837-853.
3. The Diabetes Control and Complications Trial Research Group. - Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes Care, 1997, 46, 271-286.
4. Radermecker RP, Jandrain B, Paquot N, et al. - Prévention des hypoglycémies chez le patient diabétique de type 1. Rev Med Liège, 2003, 58, 361-368.
5. Cryer PE. - Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia, 2002, 45, 937-948.
6. Turner RC, Cull CA, Frighi V, Holman RR. - Glycaemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA, 1999, 281, 2005-2012.
7. Scheen AJ, Bruwier G, Schmitt H, au nom des membres de l'étude clinique DREAM. - Optimalisation de la prise en charge du patient diabétique de type 2: résultats de l'étude "DREAM" en médecine générale. Rev Med Liège, 2003, 58, 139-146.
8. DeWitt DE, Hirsch IB. - Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA, 2003, 289, 2254-2264.
9. Scheen AJ, Lefèbvre PJ. - Le diabète instable: de la physiopathologie au traitement. Rev Med Liège, 1995, 50, 249-253.
10. Philips JC, Scheen AJ. - Comment je traite ... un patient diabétique de type 1 par pompe portable à insuline. Rev Med Liège, 1996, 51, 678-680.
11. Radermecker RP, Scheen AJ. - Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness. Diabetes/Metab Res Rev, 2004, in press.
12. Bolli GB, Owens DR. - Insulin glargine. Lancet, 2000, 356, 443-445.
13. McKeage K, Goa KL. - Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and type 2 diabetes mellitus. Drugs, 2001, 61, 1599-1624.
14. Dunn CJ, Plosker GL, Keating GM et al. - Insulin glargine. An updated review of its use in the management of diabetes mellitus. Drugs, 2003, 63, 1743-1778.
15. Lepore M, Pampanelli S, Fanelli C, et al. - Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes, 2000, 49, 2142-2148.
16. Ciaraldi TP, Carter L, Seipke G, et al. - Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparison to insulin and IGF-1. J Clin Endocrinol Metab, 2001, 86, 5838-5847.
17. Ratner RE, Hirsch IB, Neifing JL, et al. - Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care, 2000, 23, 639-643.
18. Raskin P, Klaff L, Bergental R et al. - A 16 week comparison of the novel insulin analog Lantus (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care, 2000, 23, 1666-1671.
19. Rossetti P, Costa E, Pampanelli S, et al. - Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care, 2003, 26, 1490-1496.
20. Yki-Järvinen H, Dressler A, Ziemen M, et al. - Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care, 2000, 23, 1130-1136.
21. Rosenstock J, Schwartz SL, Clark CM, et al. - Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care, 2001, 24, 631-636.
22. HOE 901/2004 Study Investigators Group. - Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in type 2 diabetic patients. Diabetic Med, 2003, 20, 545-551.
23. Yki-Järvinen H, Häring H-U, Johnson E, et al. - The relationship between glycemic control and hypoglycemia using insulin glargine versus NPH insulin: a meta regression analysis in type 2 diabetes. Diabetes, 2003, 52 (Suppl 1), A149, 642-P.
24. Witthaus E et al. - Treatment satisfaction and psychological well-being with Lantus compared with NPH in patients with type 1 diabetes. Diabetic Med, 2001, 18, 619-625.